vs
Pediatrix Medical Group, Inc.（MD）とUiPath, Inc.（PATH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Pediatrix Medical Group, Inc.の直近四半期売上が大きい（$493.8M vs $411.1M、UiPath, Inc.の約1.2倍）。UiPath, Inc.の純利益率が高く（48.4% vs 6.8%、差は41.5%）。UiPath, Inc.の前年同期比売上増加率が高い（15.9% vs -1.7%）。過去8四半期でUiPath, Inc.の売上複合成長率が高い（0.7% vs -0.1%）
Pediatrix Medical Group, Inc.は米国を代表する専門医療サービスプロバイダーで、母胎医療、新生児科、小児心臓病学などの小児亜専門を中心に事業を展開し、米国全土の医療機関と提携して女性、新生児、子どもに根拠に基づく質の高い医療を提供しています。
UiPath Inc.は人工知能（AI）、自律型オートメーションおよびオーケストレーションソフトウェアを開発するグローバルソフトウェア企業です。同社の製品は複雑な業務プロセスやワークフローを自動化するAIエージェントの構築・管理に対応し、各業界の業務効率向上を支援しています。
MD vs PATH — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $493.8M | $411.1M |
| 純利益 | $33.7M | $198.8M |
| 粗利率 | — | 83.3% |
| 営業利益率 | 9.9% | 3.2% |
| 純利益率 | 6.8% | 48.4% |
| 売上前年比 | -1.7% | 15.9% |
| 純利益前年比 | 10.5% | 1966.2% |
| EPS（希薄化後） | $0.40 | $0.37 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $493.8M | $411.1M | ||
| Q3 25 | $492.9M | $361.7M | ||
| Q2 25 | $468.8M | $356.6M | ||
| Q1 25 | $458.4M | $423.6M | ||
| Q4 24 | $502.4M | $354.7M | ||
| Q3 24 | $511.2M | $316.3M | ||
| Q2 24 | $504.3M | $335.1M | ||
| Q1 24 | $495.1M | $405.3M |
| Q4 25 | $33.7M | $198.8M | ||
| Q3 25 | $71.7M | $1.6M | ||
| Q2 25 | $39.3M | $-22.6M | ||
| Q1 25 | $20.7M | $51.8M | ||
| Q4 24 | $30.5M | $-10.7M | ||
| Q3 24 | $19.4M | $-86.1M | ||
| Q2 24 | $-153.0M | $-28.7M | ||
| Q1 24 | $4.0M | $33.9M |
| Q4 25 | — | 83.3% | ||
| Q3 25 | — | 82.2% | ||
| Q2 25 | — | 82.1% | ||
| Q1 25 | — | 84.8% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.0% | ||
| Q2 24 | — | 83.5% | ||
| Q1 24 | — | 86.8% |
| Q4 25 | 9.9% | 3.2% | ||
| Q3 25 | 13.8% | -5.6% | ||
| Q2 25 | 12.8% | -4.6% | ||
| Q1 25 | 7.0% | 7.9% | ||
| Q4 24 | 7.8% | -12.2% | ||
| Q3 24 | 6.6% | -32.7% | ||
| Q2 24 | -31.3% | -14.8% | ||
| Q1 24 | 3.2% | 3.7% |
| Q4 25 | 6.8% | 48.4% | ||
| Q3 25 | 14.5% | 0.4% | ||
| Q2 25 | 8.4% | -6.3% | ||
| Q1 25 | 4.5% | 12.2% | ||
| Q4 24 | 6.1% | -3.0% | ||
| Q3 24 | 3.8% | -27.2% | ||
| Q2 24 | -30.3% | -8.6% | ||
| Q1 24 | 0.8% | 8.4% |
| Q4 25 | $0.40 | $0.37 | ||
| Q3 25 | $0.84 | $0.00 | ||
| Q2 25 | $0.46 | $-0.04 | ||
| Q1 25 | $0.24 | $0.09 | ||
| Q4 24 | $0.37 | $-0.02 | ||
| Q3 24 | $0.23 | $-0.15 | ||
| Q2 24 | $-1.84 | $-0.05 | ||
| Q1 24 | $0.05 | $0.07 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $375.2M | $1.4B |
| 総負債低いほど良い | $570.5M | — |
| 株主資本純資産 | $865.9M | $1.9B |
| 総資産 | $2.2B | $2.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.66× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $375.2M | $1.4B | ||
| Q3 25 | $340.1M | $1.4B | ||
| Q2 25 | $224.7M | $1.6B | ||
| Q1 25 | $99.0M | $1.6B | ||
| Q4 24 | $229.9M | $1.6B | ||
| Q3 24 | $103.8M | $1.7B | ||
| Q2 24 | $19.4M | $1.9B | ||
| Q1 24 | $8.0M | $1.9B |
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $865.9M | $1.9B | ||
| Q3 25 | $890.7M | $1.7B | ||
| Q2 25 | $833.8M | $1.7B | ||
| Q1 25 | $789.2M | $1.8B | ||
| Q4 24 | $764.9M | $1.7B | ||
| Q3 24 | $732.5M | $1.8B | ||
| Q2 24 | $706.5M | $2.0B | ||
| Q1 24 | $856.2M | $2.0B |
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.2B | $2.6B | ||
| Q2 25 | $2.1B | $2.6B | ||
| Q1 25 | $2.0B | $2.9B | ||
| Q4 24 | $2.2B | $2.7B | ||
| Q3 24 | $2.1B | $2.7B | ||
| Q2 24 | $2.0B | $2.8B | ||
| Q1 24 | $2.2B | $3.0B |
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $114.1M | $28.3M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $25.1M |
| FCFマージンFCF / 売上 | — | 6.1% |
| 設備投資強度設備投資 / 売上 | — | 0.8% |
| キャッシュ転換率営業CF / 純利益 | 3.39× | 0.14× |
| 直近12ヶ月FCF直近4四半期 | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $114.1M | $28.3M | ||
| Q3 25 | $137.3M | $41.6M | ||
| Q2 25 | $137.2M | $119.0M | ||
| Q1 25 | $-117.5M | $146.1M | ||
| Q4 24 | $133.0M | $28.1M | ||
| Q3 24 | $91.8M | $46.4M | ||
| Q2 24 | $107.0M | $100.0M | ||
| Q1 24 | $-125.2M | $145.6M |
| Q4 25 | — | $25.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $106.2M | ||
| Q1 25 | — | $138.7M | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | — | $45.0M | ||
| Q2 24 | — | $98.8M | ||
| Q1 24 | — | $141.8M |
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 29.8% | ||
| Q1 25 | — | 32.7% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | — | 29.5% | ||
| Q1 24 | — | 35.0% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 3.6% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | 3.39× | 0.14× | ||
| Q3 25 | 1.91× | 26.25× | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | -5.66× | 2.82× | ||
| Q4 24 | 4.36× | — | ||
| Q3 24 | 4.72× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -31.03× | 4.29× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
